NCT03916419View on ClinicalTrials.gov

Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

June 20, 2019

Primary Completion Date

September 25, 2025

Study Completion Date

September 25, 2025

Conditions
Stage IIB Non-Small Cell Lung CancerStage IIIA Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IIIC Non-Small Cell Lung Cancer
Interventions
DEVICE

ViewRay MR-Linear Accelerator

-Radiation will be delivered by this machine

RADIATION

Radiation therapy

-60Gy in 15 fractions

DRUG

Paclitaxel

-50 mg/m\^2 intravenous

DRUG

Carboplatin AUC

-2 mg/mL/min intravenous over 30 minutes

BIOLOGICAL

Durvalumab

-10 mg/kg

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER

NCT03916419 - Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter